Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Bought by Davidson Capital Management Inc.

Davidson Capital Management Inc. raised its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 14,012.1% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 26,813 shares of the biopharmaceutical company's stock after buying an additional 26,623 shares during the period. Davidson Capital Management Inc.'s holdings in Halozyme Therapeutics were worth $1,535,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. GAMMA Investing LLC boosted its holdings in Halozyme Therapeutics by 96.6% in the second quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 254 shares during the period. Fifth Third Bancorp raised its holdings in Halozyme Therapeutics by 2.4% in the second quarter. Fifth Third Bancorp now owns 11,206 shares of the biopharmaceutical company's stock valued at $587,000 after acquiring an additional 261 shares in the last quarter. Private Advisor Group LLC lifted its stake in Halozyme Therapeutics by 1.8% in the second quarter. Private Advisor Group LLC now owns 22,753 shares of the biopharmaceutical company's stock worth $1,191,000 after acquiring an additional 412 shares during the last quarter. Juncture Wealth Strategies LLC grew its holdings in Halozyme Therapeutics by 3.6% during the 3rd quarter. Juncture Wealth Strategies LLC now owns 12,058 shares of the biopharmaceutical company's stock worth $690,000 after acquiring an additional 415 shares in the last quarter. Finally, Diversify Advisory Services LLC increased its position in shares of Halozyme Therapeutics by 8.5% in the 3rd quarter. Diversify Advisory Services LLC now owns 5,331 shares of the biopharmaceutical company's stock valued at $305,000 after purchasing an additional 418 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company's stock.

Insider Activity at Halozyme Therapeutics

In related news, CEO Helen Torley sold 10,000 shares of the stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $52.58, for a total transaction of $525,800.00. Following the completion of the sale, the chief executive officer now owns 676,744 shares of the company's stock, valued at approximately $35,583,199.52. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Matthew L. Posard sold 9,881 shares of the business's stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $57.70, for a total transaction of $570,133.70. Following the transaction, the director now directly owns 69,874 shares of the company's stock, valued at approximately $4,031,729.80. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Helen Torley sold 10,000 shares of the business's stock in a transaction on Wednesday, October 9th. The stock was sold at an average price of $52.58, for a total transaction of $525,800.00. Following the completion of the transaction, the chief executive officer now owns 676,744 shares in the company, valued at $35,583,199.52. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 89,881 shares of company stock worth $5,169,834. 2.40% of the stock is owned by insiders.

Halozyme Therapeutics Trading Up 0.4 %

HALO traded up $0.18 during midday trading on Tuesday, hitting $50.64. The company's stock had a trading volume of 538,214 shares, compared to its average volume of 1,274,995. The firm has a market cap of $6.45 billion, a P/E ratio of 20.87, a PEG ratio of 0.50 and a beta of 1.27. Halozyme Therapeutics, Inc. has a 52-week low of $33.07 and a 52-week high of $65.53. The company has a current ratio of 7.41, a quick ratio of 6.21 and a debt-to-equity ratio of 5.19. The firm has a 50-day moving average price of $57.76 and a two-hundred day moving average price of $51.75.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.73 by $0.18. The firm had revenue of $231.40 million during the quarter, compared to the consensus estimate of $204.94 million. Halozyme Therapeutics had a net margin of 38.62% and a return on equity of 195.80%. Halozyme Therapeutics's revenue was up 4.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.68 earnings per share. On average, research analysts anticipate that Halozyme Therapeutics, Inc. will post 3.71 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently commented on HALO shares. The Goldman Sachs Group increased their target price on Halozyme Therapeutics from $44.00 to $49.00 and gave the company a "neutral" rating in a report on Monday, July 22nd. TD Cowen upped their price target on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the company a "buy" rating in a research report on Wednesday, August 7th. JPMorgan Chase & Co. downgraded Halozyme Therapeutics from an "overweight" rating to a "neutral" rating and upped their price objective for the company from $52.00 to $57.00 in a research note on Thursday, September 19th. Benchmark reaffirmed a "buy" rating and issued a $60.00 target price on shares of Halozyme Therapeutics in a report on Thursday, August 8th. Finally, Morgan Stanley increased their price target on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the stock an "overweight" rating in a report on Wednesday, August 7th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, Halozyme Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $60.44.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.